NSI-189 vs Dihexa

NSI-189 wins for: Documented safety in clinical trials, structural hippocampal neurogenesis, well-tolerated side effect profile, mild but persistent effects, and suitability for mood-focused protocols.

Dihexa wins for: Potency in synaptogenic action, rapid structural changes at low doses, application in learning or post-injury recovery scenarios, and unique HGF/c-Met mechanism (though with serious caveats on cancer risk and study retraction).

Pick NSI-189 if:

• The goal is durable hippocampal neurogenesis backed by published phase data.
• Recovery from post-SSRI anhedonia, mild cognitive impairment, or persistent mood flattening is the primary aim.
• A safety-first approach with long-term follow-up data is critical.
• Side effect tolerability, lack of stimulant action, and milder ramp-up are desired.
• Protocols involve mood or emotional reactivity more than peak memory.

Pick Dihexa if:

• Synaptogenic potency for intense cognitive-recovery, learning phases, or skill acquisition is needed.
• Post-concussion or post-neurotoxic protocols seek structural CNS repair beyond neurogenesis.
• There is zero personal/family cancer risk, and short high-impact cycles are viable.
• The novelty of the HGF/c-Met pathway is a selling point, and stacking with other nootropics is acceptable.
• Willingness to source from less vetted channels and accept data gaps for short cycles.